COVID19 in patients affected by lymphoma represents an important challenge because of the higher mortality rate. Anti‐SARS‐CoV‐2 monoclonal antibodies (anti‐S MoAbs) appear promising in this setting. We report a monocentric retrospective study including 176 patients affected by lymphoma which developed SARS‐CoV‐2 infection since the start of COVID19 pandemic. Overall, mortality was 13.1%, with a decreasing trend between first waves to the last wave of pandemic (18.5% vs. 9.4%, p 0.076). Patients receiving anti‐S MoAbs (41.3%) showed inferior mortality rate (overall survival, OS 93.2% vs. 82.7%, p 0.025) with no serious toxicity, reduced documented pneumonia (26% vs. 33%, p 0.005), and reduced need of oxygen support (14.5% vs. 35.7%, p 0.003). Among patients who received 3 doses of vaccine, the employment of anti‐COVID MoAbs showed a trend of superior survival versus those who did not receive Anti‐S MoAbs (OS rates 97.3% vs. 84.2%, p 0.064). On multivariate analysis, active haematological disease (OS 72% (HR 2.49 CI 1.00–6.41), bendamustine exposure (OS 60% HR 4.2 CI 1.69–10.45) and at least one comorbidity (HR 6.53 CI 1.88–22.60) were independent prognostic factors for death. Our study confirms the adverse prognostic role of COVID‐19 in lymphoma patients in presence of active disease, comorbidities and previous exposure to bendamustine. In our experience, anti‐S MoAbs represented a therapeutic option in vaccinated patients.